Want to see CH:CURN full AI Analyst Report?
Curatis Holding AG (CURN) AI Stock Analysis
Curatis Holding AG
(Six Swiss:CURN)
The company's improving fundamentals and debt-free balance sheet are significant strengths, but these are offset by persistent negative cash flow, weak technical momentum, and a poor valuation due to current unprofitability. The stock is in a transitional phase with high risk.
Curatis Holding AG (CURN) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 90.59M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,776
- Price to Earnings (P/E)
- -134.1
- Beta (1Y)
- -0.21
- Revenue Growth
- 32.84%
- EPS Growth
- 61.88%
- Country
- Switzerland
- Employees
- 9
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Curatis Holding AG Business Overview & Revenue Model
Company Description
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized m...
Curatis Holding AG Financial Statement Overview
Summary
Financial performance is mixed but improving. The income statement shows strong revenue growth and narrowing losses, and the balance sheet is pristine with no debt. However, negative cash flow remains a concern, pulling the overall financial score to a moderate level.
Income Statement
65PositiveBalance Sheet
85Very PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.50M | 10.80M | 6.90M | 0 | 0 | 0 |
| Gross Profit | 218.00K | 2.84M | 1.59M | 0 | -1.52M | 0 |
| EBITDA | -271.00K | -1.13M | -4.34M | -38.34M | -38.37M | -130.00K |
| Net Income | -658.00K | -1.42M | -4.34M | -49.38M | -34.73M | 137.00K |
Balance Sheet | ||||||
| Total Assets | 57.86M | 55.96M | 55.54M | 120.00K | 14.05M | 136.00K |
| Cash, Cash Equivalents and Short-Term Investments | 3.60M | 1.87M | 3.01M | 9,000 | 1.34M | 124.00K |
| Total Debt | 0 | 0 | 0 | 133.00K | 3.00M | 429.00K |
| Total Liabilities | 9.11M | 9.88M | 9.94M | 432.00K | 7.29M | 536.00K |
| Stockholders Equity | 48.75M | 46.08M | 45.60M | -312.00K | 6.75M | -400.00K |
Cash Flow | ||||||
| Free Cash Flow | -1.14M | -2.53M | -825.00K | -1.89M | -4.66M | -359.00K |
| Operating Cash Flow | -1.14M | -1.31M | -825.00K | -1.89M | -4.65M | -359.00K |
| Investing Cash Flow | -1.62M | -1.22M | 4.01M | -6,000 | 5.48M | 0 |
| Financing Cash Flow | 4.32M | 1.38M | -183.00K | 558.00K | 392.00K | 420.00K |
Curatis Holding AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:CURN, the sentiment is Negative. The current price of 17.05 is below the 20-day moving average (MA) of 17.66, below the 50-day MA of 18.64, and below the 200-day MA of 20.67, indicating a bearish trend. The MACD of -0.48 indicates Negative momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 59.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:CURN.
Curatis Holding AG Peers Comparison
Overall Rating
- CH:CURN55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| CH:CURN | 55Neutral | CHF 90.56M | -134.15 | ― | ― | 32.84% | 61.88% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:CURN | Curatis Holding AG | 17.05 | 3.90 | 29.66% |
Curatis Holding AG Corporate Events
Curatis posts record half-year and accelerates corticorelin programme
Curatis reported its strongest half-year to date, with net sales rising 51% to CHF 7.9 million and the loss narrowing to CHF 0.4 million, supported by expanded distribution products and improved gross margins. A CHF 3.0 million convertible instrument...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026